NPJ Vaccines . The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination

[tetano]

NPJ Vaccines


. 2022 Aug 30;7(1):103.
doi: 10.1038/s41541-022-00524-7.
The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination


Johannes B Goll ¹ , Aarti Jain ² , Travis L Jensen ¹ , Rafael Assis ² , Rie Nakajima ² , Algis Jasinskas ² , Lynda Coughlan ^{3 4} , Sami R Cherikh ¹ , Casey E Gelber ¹ , S Khan ² , D Huw Davies ² , Philip Meade ⁵ , Daniel Stadlbauer ^{5 6} , Shirin Strohmeier ⁵ , Florian Krammer ⁵ , Wilbur H Chen ³ , Philip L Felgner ⁷



Affiliations

• PMID: 36042229
• DOI: 10.1038/s41541-022-00524-7

Abstract

Current seasonal and pre-pandemic influenza vaccines induce short-lived predominantly strain-specific and limited heterosubtypic responses. To better understand how vaccine adjuvants AS03 and MF59 may provide improved antibody responses to vaccination, we interrogated serum from subjects who received 2 doses of inactivated monovalent influenza A/Indonesia/05/2005 vaccine with or without AS03 or MF59 using hemagglutinin (HA) microarrays (NCT01317758 and NCT01317745). The arrays were designed to reflect both full-length and globular head HA derived from 17 influenza A subtypes (H1 to H16 and H18) and influenza B strains. We observed significantly increased strain-specific and broad homo- and heterosubtypic antibody responses with both AS03 and MF59 adjuvanted vaccination with AS03 achieving a higher titer and breadth of IgG responses relative to MF59. The adjuvanted vaccine was also associated with the elicitation of stalk-directed antibody. We established good correlation of the array antibody responses to H5 antigens with standard HA inhibition and microneutralization titers.